Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

NCT01415882 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

165

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions

DRUG: Cyclophosphamide
BIOLOGICAL: Daratumumab
DRUG: Dexamethasone
DRUG: Ixazomib Citrate
OTHER: Laboratory Biomarker Analysis

Sponsor

Mayo Clinic